Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1744-859X
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece ; volume:11 ; number:1 ; day:2 ; month:7 ; year:2012 ; pages:1-8 ; date:12.2012
Annals of general psychiatry ; 11, Heft 1 (2.7.2012), 1-8, 12.2012

Urheber
Einarson, Thomas R.
Geitona, Maria
Chaidemenos, Alexandros
Karpouza, Vasiliki
Mougiakos, Theodoros
Paterakis, Periklis
Ploumpidis, Dimitrios
Potamitis-Komis, Dionyssios
Zilbershtein, Roman
Vicente, Colin
Piwko, Charles
Kakkavas, Panagiotis
Paparouni, Konstantina
Jensen, Rasmus C D.
Hemels, Michiel E H.
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1186/1744-859X-11-18
URN
urn:nbn:de:101:1-2019062721003448273079
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 10:59 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Einarson, Thomas R.
  • Geitona, Maria
  • Chaidemenos, Alexandros
  • Karpouza, Vasiliki
  • Mougiakos, Theodoros
  • Paterakis, Periklis
  • Ploumpidis, Dimitrios
  • Potamitis-Komis, Dionyssios
  • Zilbershtein, Roman
  • Vicente, Colin
  • Piwko, Charles
  • Kakkavas, Panagiotis
  • Paparouni, Konstantina
  • Jensen, Rasmus C D.
  • Hemels, Michiel E H.
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Paliperidone Palmitate Improves and Maintains Functioning in Asia–Pacific Patients with Schizophrenia

Paliperidone Palmitate Improves and Maintains Functioning in Asia–Pacific Patients with Schizophrenia

Treating Negative Symptoms in Schizophrenia: an Update

Treating Negative Symptoms in Schizophrenia: an Update

Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate

Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate

Factors Associated with Symptom Stabilization that Allow for Successful Transition from Once-Monthly Paliperidone Palmitate to Three-Monthly Paliperidone Palmitate: A Post Hoc Analysis Examined Clinical Characteristics in Chinese Patients with Schizophrenia

Factors Associated with Symptom Stabilization that Allow for Successful Transition from Once-Monthly Paliperidone Palmitate to Three-Monthly Paliperidone Palmitate: A Post Hoc Analysis Examined Clinical Characteristics in Chinese Patients with Schizophrenia

Health economics study of paliperidone palmitate in the treatment of schizophrenia: a 12-month cohort study

Health economics study of paliperidone palmitate in the treatment of schizophrenia: a 12-month cohort study

Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies

Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies

Costs and Resource Utilization Among Medicaid Patients with Schizophrenia Treated with Paliperidone Palmitate or Oral Atypical Antipsychotics

Costs and Resource Utilization Among Medicaid Patients with Schizophrenia Treated with Paliperidone Palmitate or Oral Atypical Antipsychotics

Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate

Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate

Upregulated hepatic lipogenesis from dietary sugars in response to low palmitate feeding supplies brain palmitate

Upregulated hepatic lipogenesis from dietary sugars in response to low palmitate feeding supplies brain palmitate

Characteristics of patients with schizophrenia switching from oral antipsychotics to once-monthly paliperidone palmitate (PP1M): a systematic review

Characteristics of patients with schizophrenia switching from oral antipsychotics to once-monthly paliperidone palmitate (PP1M): a systematic review

Human health benefit and burden of the schizophrenia health care pathway in Belgium: paliperidone palmitate long-acting injections

Human health benefit and burden of the schizophrenia health care pathway in Belgium: paliperidone palmitate long-acting injections

Paliperidone palmitate vs. paliperidone extended-release for the acute treatment of adults with schizophrenia: a systematic review and pairwise and network meta-analysis

Paliperidone palmitate vs. paliperidone extended-release for the acute treatment of adults with schizophrenia: a systematic review and pairwise and network meta-analysis

Verbundene Objekte